bluebird bio, Inc.
BLUE
$4.95
$0.061.23%
| Weiss Ratings | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.94 | |||
| Price History | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 32.00% | |||
| 30-Day Total Return | 21.32% | |||
| 60-Day Total Return | -45.12% | |||
| 90-Day Total Return | -16.92% | |||
| Year to Date Total Return | -43.04% | |||
| 1-Year Total Return | -79.88% | |||
| 2-Year Total Return | -92.07% | |||
| 3-Year Total Return | -95.27% | |||
| 5-Year Total Return | -99.12% | |||
| 52-Week High % Change | -82.90% | |||
| 52-Week Low % Change | 37.36% | |||
| Price | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $28.60 | |||
| 52-Week Low Price | $3.56 | |||
| 52-Week Low Price (Date) | Feb 24, 2025 | |||
| 52-Week High Price (Date) | Jul 16, 2024 | |||
| Valuation | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 47.87M | |||
| Enterprise Value | 356.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -24.86 | |||
| Earnings Per Share Growth | -33.96% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.57 | |||
| Price/Book (Q) | -1.51 | |||
| Enterprise Value/Revenue (TTM) | 4.25 | |||
| Price | $4.95 | |||
| Enterprise Value/EBITDA (TTM) | -1.72 | |||
| Enterprise Value/EBIT | -1.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 9.72M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 339 499 9300 | |||
| Address | 455 Grand Union Boulevard Somerville, MA 02145 | |||
| Website | www.bluebirdbio.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -319.42% | |||
| Profit Margin | -287.22% | |||
| Management Effectiveness | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.00% | |||
| Return on Equity | -- | |||
| Income Statement | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 83.80M | |||
| Total Revenue (TTM) | 83.81M | |||
| Revenue Per Share | $8.62 | |||
| Gross Profit (TTM) | -5.57M | |||
| EBITDA (TTM) | -206.46M | |||
| EBIT (TTM) | -267.70M | |||
| Net Income (TTM) | -240.72M | |||
| Net Income Avl. to Common (TTM) | -240.72M | |||
| Total Revenue Growth (Q YOY) | 391.72% | |||
| Earnings Growth (Q YOY) | 64.48% | |||
| EPS Diluted (TTM) | -24.86 | |||
| EPS Diluted Growth (Q YOY) | 78.34% | |||
| Balance Sheet | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 62.31M | |||
| Cash Per Share (Q) | $6.41 | |||
| Total Current Assets (Q) | 154.67M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -31.53M | |||
| Current Ratio (Q) | 0.481 | |||
| Book Value Per Share (Q) | -$3.24 | |||
| Total Assets (Q) | 460.23M | |||
| Total Current Liabilities (Q) | 321.46M | |||
| Total Debt (Q) | 370.53M | |||
| Total Liabilities (Q) | 491.77M | |||
| Total Common Equity (Q) | -31.53M | |||
| Cash Flow | BLUE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.90M | |||
| Cash from Financing (TTM) | 87.47M | |||
| Net Change in Cash (TTM) | -168.65M | |||
| Levered Free Cash Flow (TTM) | -112.38M | |||
| Cash from Operations (TTM) | -260.02M | |||
